|
| 36610996 | A polygenic two-hit hypothesis for prostate cancer. | J Natl Cancer Inst | 2023 |
| 37890967 | Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol. | BMJ Open | 2023 |
| 36230886 | Molecular Mechanisms Driving the Formation of Brain Metastases. | Cancers (Basel) | 2022 |
| 35574563 | A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia. | Alzheimers Dement (N Y) | 2022 |
| 35688680 | Phase 2 Study of Neoadjuvant FGFR Inhibition and Androgen Deprivation Therapy Prior to Prostatectomy. | Clin Genitourin Cancer | 2022 |
| 35659150 | Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study. | Eur Urol | 2022 |
| 35811101 | Identification and isolation of slow-cycling glioma stem cells. | Methods Cell Biol | 2022 |
| 36103484 | Perish and publish: Dynamics of biomedical publications by deceased authors. | PLoS One | 2022 |
| 33389014 | Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. | Cancer Immunol Immunother | 2021 |
| 35474657 | Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management. | BJUI Compass | 2021 |
| 33678516 | Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. | Eur J Cancer | 2021 |
| 34916328 | Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial. | BMJ Open | 2021 |
| 35008330 | Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer. | Cancers (Basel) | 2021 |
| 34988458 | Sodium selenate as a disease-modifying treatment for mild-moderate Alzheimer's disease: an open-label extension study. | BMJ Neurol Open | 2021 |
| 34322653 | Loss of <i>SNAI2</i> in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy. | JCO Precis Oncol | 2021 |
| 34294073 | Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression. | BMC Cancer | 2021 |
| 34310033 | The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade. | BJU Int | 2021 |
| 34108644 | MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. | Prostate Cancer Prostatic Dis | 2021 |
| 33419682 | The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. | Eur Urol | 2021 |
| 32314873 | Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. | EMBO Rep | 2020 |
| 32807235 | Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. | Genome Med | 2020 |
| 32392735 | The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. | Cancers (Basel) | 2020 |
| 30382379 | Developments in oligometastatic hormone-sensitive prostate cancer. | World J Urol | 2019 |
| 30215171 | Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. | Neurotherapeutics | 2019 |
| 30248237 | Late biochemical recurrence after radical prostatectomy is associated with a slower rate of progression. | BJU Int | 2019 |
| 30772200 | Prostatic nerve subtypes independently predict biochemical recurrence in prostate cancer. | J Clin Neurosci | 2019 |
| 30959474 | Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat. | Endocr Connect | 2019 |
| 30642810 | What Is Oligometastatic Prostate Cancer? | Eur Urol Focus | 2019 |
| 30562483 | Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance. | Exp Cell Res | 2019 |
| 29592867 | Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer. | Endocr Relat Cancer | 2018 |
| 30596026 | Preparation of fluorescent in situ hybridisation probes without the need for optimisation of fragmentation. | MethodsX | 2018 |
| 29661963 | Obesity suppresses tumor attributable PSA, affecting risk categorization. | Endocr Relat Cancer | 2018 |
| 27431748 | Routinely reported 'equivocal' lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes. | BJU Int | 2017 |
| 29050365 | Mitochondrial genome variation and prostate cancer: a review of the mutational landscape and application to clinical management. | Oncotarget | 2017 |
| 28710841 | Accelerated kindling epileptogenesis in Tg4510 tau transgenic mice, but not in tau knockout mice. | Epilepsia | 2017 |
| 27896520 | Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin. | J Neurooncol | 2017 |
| 27864419 | How Subclonal Modeling Is Changing the Metastatic Paradigm. | Clin Cancer Res | 2017 |
| 27824348 | Androgen synthesis in prostate cancer: do all roads lead to Rome? | Nat Rev Urol | 2017 |
| 27554242 | Disrupting the Status Quo in Prostate Cancer Diagnosis. | Eur Urol | 2017 |
| 26812572 | A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. | Br J Cancer | 2016 |
| 28881726 | Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer. | Oncotarget | 2016 |
| 27653089 | Comparing nodal versus bony metastatic spread using tumour phylogenies. | Sci Rep | 2016 |
| 27120785 | Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression. | Oncotarget | 2016 |
| 27169997 | Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis. | Clin Cancer Res | 2016 |
| 27447428 | A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease. | J Alzheimers Dis | 2016 |
| 27289302 | Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau. | Brain | 2016 |
| 27163189 | Sodium selenate, a protein phosphatase 2A activator, mitigates hyperphosphorylated tau and improves repeated mild traumatic brain injury outcomes. | Neuropharmacology | 2016 |
| 25444993 | Repair mechanisms help glioblastoma resist treatment. | J Clin Neurosci | 2015 |
| 26308396 | Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme. | J Clin Neurosci | 2015 |
| 25882061 | Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer. | Curr Cancer Drug Targets | 2015 |